Spyre Therapeutics Inc. stocks have been trading up by 6.19 percent amid heightened optimism from its latest clinical trial progress
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Part A of the Phase 2 SKYLINE trial for SPY002 in ulcerative colitis hit its primary endpoint, with strong RHI reduction, remission, and endoscopic improvement plus class‑consistent safety.
- Deutsche Bank lifted its Spyre Therapeutics price target to $135 from $115, adding a third IBD combination therapy into its SYRE valuation ahead of IL‑23 data.
- Wedbush and BTIG each raised SYRE targets to $100 and $112, respectively, after positive SPY002 data and boosted probabilities of success across multiple TL1A programs.
- SYRE shares slid more than 13% on heavy volume after filings showed sizable insider stock sales by a director, followed by additional CEO and CFO sales.
- New equity awards and hires show Spyre Therapeutics continuing to build out its team as it advances its TL1A pipeline.
Live Update At 16:03:01 EDT: On Tuesday, July 07, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 6.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
SYRE is trading like a classic high‑expectation biotech. Over the last several weeks, Spyre Therapeutics has swung from the low $80s to above $100 and back into the $80–$90 zone. The recent close around $94.23 caps a multi‑day rebound from a sharp selloff tied to insider sales, not new clinical data.
On the intraday tape, SYRE spent most of the latest session grinding higher in a tight channel. After an early dip from $90 to the high $80s, buyers steadily stepped in, walking the stock back toward the mid‑$90s into the close. That tells traders there is real dip‑buying interest near the high‑80s support area.
More Breaking News
- CRDO Stock Draws Aggressive Price Targets As AI Connectivity Bet Heats Up
- BJDX Stock Slides As Traders Focus On Cash Runway And Volatility
- AMPG Stock Pulls Back As Traders Watch Key Support
- BFLY Stock Draws Traders As Brazil Launch And Licensing Deals Build Momentum
Fundamentally, Spyre Therapeutics is still a development‑stage name. The company posted a quarterly net loss of about $69.0M and negative free cash flow near $57.4M as it spends heavily on R&D. But SYRE also ended the quarter with roughly $741.5M in cash and short‑term investments and no long‑term debt, plus a strong current ratio around 9. For active traders, that cash runway and clean balance sheet reduce near‑term financing risk, keeping the focus on trial results and sentiment swings.
Why Traders Are Watching SYRE Right Now
SYRE is on a lot of biotech watchlists because of one core driver: SPY002. Spyre Therapeutics reported that Part A of its Phase 2 SKYLINE trial in ulcerative colitis met the primary endpoint, with statistically significant RHI score reduction and high clinical remission and endoscopic improvement rates. Just as important, SPY002’s safety lined up with the broader TL1A class. In simple terms, the drug worked and did not show new safety surprises. That’s the fuel behind the Street’s recent target hikes.
Right after those data, Wedbush raised its Spyre Therapeutics price target to $100 from $80 and reiterated an Outperform rating, calling the efficacy class‑consistent. BTIG followed by lifting its target on SYRE from $98 to $112, explicitly upping modeled probabilities of success for TL1A assets in ulcerative colitis, Crohn’s disease, and rheumatoid arthritis, and even lowering its discount rate. When a bank cuts the discount rate in a biotech model, it is effectively saying, “We see this program as less risky now.”
Deutsche Bank then pushed the narrative further, taking its Spyre Therapeutics target to $135 from $115 after adding a third inflammatory bowel disease combination therapy into its valuation ahead of IL‑23 data. That tells traders the Street is not just paying for SPY002 monotherapy. Analysts are starting to view SYRE as a platform story with multiple shots on goal.
There is also a strategic angle. BTIG highlighted that M&A interest in Apogee Therapeutics is a positive read‑through for other Paragon Therapeutics spinouts, including Spyre Therapeutics. For traders who like takeover optionality and ecosystem plays, SYRE now sits squarely in that conversation.
Conclusion
For all that bullish backdrop, the SYRE chart reminds traders that tape and thesis do not always move together. Spyre Therapeutics dropped more than 13% on heavy volume after a filing showed director Michael Thomas Henderson sold 20,000 shares for about $2M. Subsequent Form 4 filings revealed another 15,000 shares sold by CEO Cameron Turtle and 15,000 by CFO Scott L. Burrows. Insider selling does not automatically equal trouble, but in a momentum biotech like SYRE it often triggers fast, emotional selling.
At the same time, Wall Street still carries a consensus Buy view on Spyre Therapeutics, with mean targets clustered in the mid‑$90s to low‑$100s, above where SYRE has recently traded. That spread, combined with solid cash, aggressive R&D spend, new hires receiving equity awards, and de‑risking SPY002 data, sets up a classic tug‑of‑war between longer‑term pipeline bulls and short‑term sentiment traders. As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.”, and SYRE’s recent action is a clear reminder that recognizing those patterns requires tracking both the story and the tape over time.
For active traders, SYRE is now a textbook “trade the catalysts, respect the risk” setup. As Tim Sykes loves to say, “Traders who last are the ones who take the time to really understand the story but still cut losses quickly when the price action disagrees.” Spyre Therapeutics is giving the market a strong story in TL1A and inflammatory disease. The rest will be decided, as always, on the chart.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.